# Flow Cytometry Shared Resource (FCSR)

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2020 · $273,136

## Abstract

FLOW CYTOMETRY SHARED RESOURCE (FCSR)
ABSTRACT
The UCLA Jonsson Comprehensive Cancer Center (JCCC) Flow Cytometry Shared Resource (FCSR) provides
continuously updated, state-of-the-art instrumentation, expertise, and training at a reduced recharge rate to
JCCC investigators whose research requires flow cytometry, mass cytometry, imaging cytometry, or cell sorting.
The FCSR is one of the longest running core facilities at UCLA and it has been servicing the needs of the JCCC
cancer research community since its inception in 1988. In 2015, Zoran Galic, PhD (ZY) became the FCSR
Director and he oversees all of the operations of the facility. Alejandro Garcia, PhD, FCSR Co-Director and
Facility Manager, is responsible for FCSR daily operations and assists Galic with long-term core planning. The
FCSR currently houses an ImageStream imaging cytometer, a Helios mass cytometer, an Attune NxT flow
cytometer, two LSR II cell analyzers, an LSR Fortessa cell analyzer, three Aria high-speed cell sorters, one of
which is enclosed in a biocontainment hood, and a RoboSep magnetic cell separator. The FCSR also established
a separate office for data analysis with two high-end computer workstations capable of processing large data
sets generated by the ImageStream imaging cytometer. FCSR personnel have >80 years of combined flow
cytometry experience and they provide expert guidance to JCCC investigators through one-on-one
consultations, educational classes, an information-rich website, and “how-to” poster presentations. Workshops,
seminars, and tutorials organized by the FCSR ensure that researchers remain on the leading edge of cytometry.
The FCSR has a broad user base and during 2013 – 2018, the FCSR supported many JCCC investigator projects
from all six JCCC Research Programs. JCCC member usage is 78% of the total Shared Resource usage. FCSR
support activities helped to enable 333 publications, of which 175 (53%) were in high-impact (IF ≥10, or field
leading) journals. FCSR leaders work with the Dean’s office in the David Geffen School of Medicine and
additional centers on campus to contain costs and provide high quality services for JCCC investigator studies.
During the prior project period, the FCSR supported numerous JCCC research teams to advance impactful
preclinical studies to the clinic. One inter-programmatic investigation showed that a combination of an immune
checkpoint inhibitor with BRAF plus MEK signaling pathway inhibitors in a mouse model of BRAF-mutant
melanoma was superior to either treatment alone. Based on these results, two Phase I clinical trials and three
larger industry sponsored randomized trials are underway. Separately, the FCSR supported intra-programmatic
preclinical studies on checkpoint inhibitors and dendritic cell vaccines in a mouse model of intracranial glioma.
Based on this work a randomized, multi-institution trial established that neoadjuvant pembrolizumab significantly
extended patients overall survival compared to a control gr...

## Key facts

- **NIH application ID:** 9936714
- **Project number:** 2P30CA016042-44
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Zoran Galic
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $273,136
- **Award type:** 2
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9936714

## Citation

> US National Institutes of Health, RePORTER application 9936714, Flow Cytometry Shared Resource (FCSR) (2P30CA016042-44). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9936714. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*